Evidence-based Treatment of High Risk Non-Disabling Ischemic Cerebrovascular Events

doi:10.3969/j.issn.1673-5765.2018.05.014

Abstract

Abstract:

The incidence and recurrence rate of high risk of disabling ischemic cerebrovascular events (HR-NICE) are high. The guidelines of both home and abroad suggest that the early comprehensive evaluation, intervention and establishing NICE management system will obtain great benefit. Several studies have revealed the efficacy and safety of antiplatelet medication, and choosing anticoagulation or thrombolysis treatment according to different cause, which may improve the prognosis. This article briefly reviews the evidence-based medicine in management of HR-NICE.

Key words: High risk non-disabling ischemic cerebrovascular events; Comprehensive management system; Antithrombotic therapy; Secondary prevention; Thrombolysis

摘要：

高危非致残性缺血性脑血管事件（high r isk n on-disabling ischemic cerebrovascular events， HR-NICE）具有发病率高、复发率高等特点，国内外指南均建议对HR-NICE人群进行快速评估、早期干预以及建立专病管理系统等综合管理。同时在治疗方面，多项研究探讨了不同抗血小板药物治疗HRNICE 人群及针对不同病因的患者采用抗凝或溶栓治疗的有效性及安全性。本文就高危非致残性缺血性脑血管事件的管理和治疗的循证医学证据作一简要综述。

关键词: 高危非致残性脑血管事件; 综合管理系统; 抗栓; 二级预防; 溶栓

MA Lin, CHEN Wei-Qi, JING Jing, WANG Yong-Jun, WANG Yi-Long. Evidence-based Treatment of High Risk Non-Disabling Ischemic Cerebrovascular Events[J]. Chinese Journal of Stroke, 2018, 13(05): 483-488.

马琳, 陈玮琪, 荆京, 王拥军, 王伊龙. 高危非致残性缺血性脑血管事件的循证医学治疗[J]. 中国卒中杂志, 2018, 13(05): 483-488.

References

[1] COULL A J，LOVETT J K，ROTHWELL P M.

Population based study of early risk of stroke

after transient ischaemic attack or minor stroke：

Implications for public education and organisation of

services[J]. BMJ，2004，328（7435）：326.

[2] ROTHWELL P M，ELIASZIW M，GUTNIKOV S

A，et al. Endarterectomy for symptomatic carotid

stenosis in relation to clinical subgroups and timing

of surgery[J]. Lancet，2004，363（9413）：915-924.

[3] LAVALLEE P C，MESEGUER E，ABBOUD H，et

al. A transient ischaemic attack clinic with roundthe-

clock access（SOS-TIA）：Feasibility and

effects[J]. Lancet Neurol，2007，6（11）：953-960.

[4] ROTHWELL P M，GILES M F，CHANDRATHEVA

A，et al. Effect of urgent treatment of transient

ischaemic attack and minor stroke on early recurrent

stroke（express study）：A prospective populationbased

sequential comparison[J]. Lancet，2007，370

（9596）：1432-1442.

[5] JOHNSTON S C，GRESS D R，BROWNER W S，et

al. Short-term prognosis after emergency department

diagnosis of TIA[J]. JAMA，2000，284（22）：2901-

2906.

[6] LUENGO F R，GRAY A M，ROTHWELL P M.

Effect of urgent treatment for transient ischaemic

attack and minor stroke on disability and hospital

costs（express study）：A prospective populationbased

sequential comparison[J]. Lancet Neurol，

2009，8（3）：235-243.

[7] MARTINEZ M M，MARTINEZ S P，FUENTES

B，et al. Transient ischaemic attacks clinics provide

equivalent and more efficient care than early inhospital

assessment[J]. Eur J Neurol，2013，20（2）：

338-343.

[8] WARRIOR L，PRABHAKARAN S. Transient

ischemic attack evaluation models：Hospitalization，

same-day clinics，or rapid evaluation units[J]. Am J

Ther，2011，18（1）：45-50.

[9] LAVALLEE P，AMARENCO P. TIA clinic：A major advance in management of transient ischemic

attacks[J/OL]. Front Neurol Neurosci，2014，33：30-

40. https：//doi.org/10.1159/000351890.

[10] AMARENCO P，LABREUCHE J，LAVALLEE

P C. Patients with transient ischemic attack with

ABCD2<4 can have similar 90-day stroke risk

as patients with transient ischemic attack with

ABCD2≥4[J]. Stroke，2012，43（3）：863-865.

[11] EASTON J D，SAVER J L，ALBERS G W，et al.

Definition and evaluation of transient ischemic attack：

a scientific statement for healthcare professionals

from the American Heart Association/American

Stroke Association Stroke Council; Council on

Cardiovascular Surgery and Anesthesia; Council on

Cardiovascular Radiology and Intervention; Council

on Cardiovascular Nursing; and the Interdisciplinary

Council on Peripheral Vascular Disease. The

American Academy of Neurology affirms the

value of this statement as an educational tool for

neurologists[J]. Stroke，2009，40（6）：2276-2293.

[12] TOUZE E，COSTE J，VOICU M，et al.

Importance of in-hospital initiation of therapies

and therapeutic inertia in secondary stroke

prevention：IMplementation of Prevention After a

Cerebrovascular evenT (IMPACT) Study[J]. Stroke，

2008，39（6）：1834-1843.

[13] BODEN A B，STILLMAN J，ROBERTS E T，et al.

Comparison of Acute Stroke Preparedness Strategies

to Decrease Emergency Department Arrival Time

in a Multiethnic Cohort：The Stroke Warning

Information and Faster Treatment Study[J]. Stroke，

2015，46（7）：1806-1812.

[14] ROSS M A，COMPTON S，MEDADO P，et al.

An emergency department diagnostic protocol

for patients with transient ischemic attack：A

randomized controlled trial[J]. Ann Emerg Med，

2007，50（2）：109-119.

[15] KENNEDY J，HILL M D，RYCKBORST K J，et

al. Fast assessment of stroke and transient ischaemic

attack to prevent early recurrence（FASTER）：A

randomised controlled pilot trial[J]. Lancet Neurol，

2007，6（11）：961-969.

[16] WANG Y，WANG Y，ZHAO X，et al. Clopidogrel

with aspirin in acute minor stroke or transient

ischemic attack[J]. N Engl J Med，2013，369（14）：

11-19.

[17] LIN J，ZHENG H，CUCCHIARA B L，et al.

Association of Lp-PLA2-A and early recurrence

of vascular events after TIA and minor stroke[J].

Neurology，2015，85（18）：1585-1591.

[18] JOHNSTON S C，EASTON J D，FARRANT M， et al. Platelet-oriented inhibition in new TIA and

minor ischemic stroke（POINT）trial：rationale and

design[J]. Int J Stroke，2013，8（6）：479-483.

[19] WANG Y，ZHAO X，LIN J，et al. Association

Between CYP2C19 Loss-of-Function Allele Status

and Efficacy of Clopidogrel for Risk Reduction

Among Patients With Minor Stroke or Transient

Ischemic Attack[J]. JAMA，2016，316（1）：70-78.

[20] The Stroke Prevention in Reversible Ischemia

Trial (SPIRIT) Study Group. A randomized trial of

anticoagulants versus aspirin after cerebral ischemia

of presumed arterial origin[J]. Ann Neurol，1997，42

（6）：857-865.

[21] DE SCHRYVER E L. Design of ESPRIT：an

international randomized trial for secondary

prevention after non-disabling cerebral ischaemia

of arterial origin. European/Australian Stroke

Prevention in Reversible Ischaemia Trial（ESPRIT）

group[J]. Cerebrovasc Dis，2000，10（2）：147-150.

[22] DE SCHRYVER E L. European/Australian Stroke

Prevention in Reversible Ischemia Trial Group.

ESPRIT：Protocol change[J]. Cerebrovasc Dis，2001，

11（3）：286.

[23] Warfarin-Aspirin Symptomatic Intracranial Disease

Trial Investigators. Design，progress and challenges

of a double-blind trial of warfarin versus aspirin

for symptomatic intracranial arterial stenosis[J].

Neuroepidemiology，2003，22（2）：106-117.

[24] SANDERCOCK P A，GIBSON L M，LIU M.

Anticoagulants for preventing recurrence following

presumed non-cardioembolic ischaemic stroke

or transient ischaemic attack[J/OL]. Cochrane

Database Syst Rev，2009：CD000248. https：//doi.

org/10.1002/14651858.CD000248.pub2.

[25] BRAVATA D M，WELLS C K，KERNAN W N，et

al. Association between impaired insulin sensitivity

and stroke[J]. Neuroepidemiology，2005，25（2）：

69-74.

[26] HANKEY G J，FENG T Z. Insulin resistance a

possible causal and treatable risk factor for ischemic

stroke[J]. Arch Neurol，2010，67（10）：1177-1178.

[27] RUNDEK T，GARDENER H，XU Q，et al. Insulin

resistance and risk of ischemic stroke among

nondiabetic individuals from the northern Manhattan

study[J]. Arch Neurol，2010，67（10）：1195-1200.

[28] THACKER E L，PSATY B M，MCKNIGHT B，et al. Fasting and post-glucose load measures of

insulin resistance and risk of ischemic stroke in older

adults[J]. Stroke，2011，42（12）：3347-3351.

[29] KERNAN W N，INZUCCHI S E，VISCOLI C

M，et al. Insulin resistance and risk for stroke[J].

Neurology，2002，59（6）：809-815.

[30] BAS D F，OZDEMIR A O，COLAK E，et al. Higher

insulin resistance level is associated with worse

clinical response in acute ischemic stroke patients

treated with intravenous thrombolysis[J]. Transl

Stroke Res，2016，7（3）：167-171.

[31] CALLEJA A I，GARCIA B P，CORTIJO E，et al.

Insulin resistance is associated with a poor response

to intravenous thrombolysis in acute ischemic

stroke[J]. Diabetes Care，2011，34（11）：2413-2417.

[32] YU A Y，HILL M D，COUTTS S B. Should minor

stroke patients be thrombolyzed? A focused review

and future directions[J]. Int J Stroke，2015，10（3）：

292-297.

[33] National Institute of Neurological Disorders Stroke

rt-PA Stroke Study Group. Recombinant tissue

plasminogen activator for minor strokes：The

National Institute of Neurological Disorders and

Stroke rt-PA Stroke Study experience[J]. Ann Emerg

Med，2005，46（3）：243-252.

[34] Khatri P，Tayama D，Cohen G，et al. Effect of

Intravenous Recombinant Tissue-Type Plasminogen

Activator in Patients With Mild Stroke in the Third

International Stroke Trial-3：Post Hoc Analysis[J].

Stroke，2015，46（8）：2325-2327.

[35] ROMANO J G，SMITH E E，LIANG L，et al.

Outcomes in mild acute ischemic stroke treated with

intravenous thrombolysis：A retrospective analysis

of the Get With the Guidelines-Stroke registry[J].

JAMA Neurol，2015，72（4）：423-431.

[36] CHOI J C，JANG M U，KANG K，et al.

Comparative effectiveness of standard care with

IV thrombolysis versus without IV thrombolysis

for mild ischemic stroke[J/OL]. J Am Heart

Assoc，2015，4：e001306. https：//doi.org/10.1161/

JAHA.114.000596.

[37] ZHAO J Z，WANG S，LI J S，et al. The perioperative

use of ceftriaxone as infection prophylaxis in

neurosurgery[J]. Clin Neurol Neurosurg，1995，97（2

Suppl）：285-289.